Livadas was appointed CEO Pharma in September 2023. He oversees the strategy and performance of Saudi Chemical Company Holding’s three pharmaceutical subsidiaries —SITCO Pharma, AJA Pharma, and CCCI. The company obtained a patent non-infringement certificate for manufacturing Ticagrelor and signed a localization agreement and mandatory listing with the Local Content & Government Procurement Authority. This has allowed the company to register this formula with the Saudi Food and Drug Authority as a fully locally manufactured product. Livadas previously held senior roles at Eli Lilly and Company.